CONNECT WITH US:
linkedin [#161]Created with Sketch.
Explore our easy-to-use
Supplier Directory
Oswego Health Promotes Sarah Driscoll to Director of Pharmacy
The Oswego Hospital Pharmacy serves patients within the hospital, Fulton and Central Square Urgent Cares, Seneca Hill Manor, Lobdell Center for Mental Health & Wellness at Lakeview, as well as Physician Care, PC
Oct 23, 2023
Sarah Driscoll

OSWEGO, NY - Oswego Health makes it a priority to recognize staff for their hard work and commitment to the organization and its patients. One key staff member who continues to shine and has truly stepped up is Sarah Driscoll.

Driscoll has been promoted to Director of Pharmacy at Oswego Health. Driscoll started at Oswego Health as a Staff Pharmacist in 2013, before transitioning in 2015 to the Pharmacy Operations Supervisor. In June of 2023 she was named Interim Director of Pharmacy.

Born and raised in Oswego, NY, Driscoll graduated with a Doctorate in Pharmacy in 2013 from Albany College of Pharmacy and Health Sciences. She has been a preceptor for the University of Buffalo School of Pharmacy, Albany College of Pharmacy, and St. John Fisher School of Pharmacy.

As the Director of Pharmacy, Driscoll will manage and direct the operations of the department to ensure that quality pharmaceutical services are provided to patients, in accordance with the mission and values of Oswego Health. Overseeing a department of seventeen, including six Pharmacists, Driscoll is looking forward to strengthening her team’s collaboration with providers and expanding the antibiotics stewardship program within the community.

The Oswego Hospital Pharmacy serves patients within the hospital, Fulton and Central Square Urgent Cares, Seneca Hill Manor, Lobdell Center for Mental Health & Wellness at Lakeview, as well as Physician Care, PC.

Latest Industry news
View all Industry News
3 bottles of Ocrevus
FDA Approves OCREVUS ZUNOVO™: First Twice-Yearly 10-Minute Injection for MS
Sep 17, 2024

Roche recently announced that the United States Food and Drug Administration (U.S. FDA) has approved OCREVUS ZUNOVO™ (ocrelizumab & hyaluronidase-ocsq) for the treatment of relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS). OCREVUS ZUNOVO is the first and only twice-a-year, healthcare professional (HCP)-administered approximately 10-minute subcutaneous (SC) injection approved for both these forms of multiple sclerosis, giving people living with MS more treatment options.

Lilly logo
Once-Weekly Insulin Efsitora Alfa Matches Daily Insulin in A1C Reduction for Adults with Type 1 Diabetes
Sep 15, 2024

INDIANAPOLIS, IN - Eli Lilly and Company announced detailed results from the QWINT-5 phase 3 trial evaluating once-weekly insulin efsitora alfa (efsitora) compared to once-daily insulin degludec in adults with type 1 diabetes who require daily basal and multiple daily mealtime insulin injections.

Tremfya box
TREMFYA® (guselkumab) receives U.S. FDA approval for adults with moderately to severely active ulcerative colitis
Sep 12, 2024

HORSHAM, PA - Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA) has approved TREMFYA® (guselkumab) for the treatment of adults with moderately to severely active ulcerative colitis (UC), a chronic disease of the large intestine in which the lining of the colon becomes inflamed. TREMFYA® is the first and only approved fully-human, dual-acting monoclonal antibody that blocks IL-23 while also binding to CD64, a receptor on cells that produce IL-23.